TransMedics Group, Inc. TMDX
- Market cap
- $2.9B
- P/E
- 19.3×
Follow TMDX
Target Price Range
Analyst price targets
Free account| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | — | — | 15.75 | 10.10 | 17.20 | 10.00 | 36.42 | 58.27 | 55.00 |
Analyst estimates 2026–2028 Powerpack |
Low Price
|
||
| — | — | — | 31.54 | 20.99 | 49.50 | 64.36 | 99.63 | 177.37 | 156.00 |
High Price
|
|||
| — | — | 92 | 109 | 110 | 148 | 212 | 584 | 728 | 898 |
Employees
|
|||
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
Revenue/Emp
|
|||
| 6 | 8 | 13 | 24 | 26 | 30 | 93 | 242 | 442 | 605 |
Revenue
|
|||
| 8.70% | 24.81% | 44.05% | 58.73% | 64.88% | 69.92% | 69.84% | 63.77% | 59.36% | 59.92% |
Gross Margin
|
|||
| (24) | (21) | (24) | (34) | (29) | (44) | (36) | (27) | 36 | 108 |
EBT
|
|||
| (387.58%) | (270.54%) | (182.18%) | (141.95%) | (112.00%) | (145.99%) | (38.70%) | (11.04%) | 8.10% | 17.76% |
EBT Margin
|
|||
| (24) | 0 | (24) | (34) | (29) | (44) | (36) | (25) | 35 | 190 |
Net Income
|
|||
| 0 | 1 | 1 | 1 | 2 | 2 | 3 | 8 | 20 | 27 |
Depreciation
|
|||
| 0.31 | 0.39 | 9.58 | 1.66 | 1.04 | 1.10 | 3.16 | 7.43 | 13.29 | 17.81 |
Revenue/Sh
|
|||
| (1.21) | (1.04) | (17.48) | (2.36) | (1.16) | (1.60) | (1.23) | (0.77) | 1.07 | 5.60 |
Earnings/Sh
|
|||
| (1.21) | (1.16) | (19.12) | (2.27) | (1.23) | (1.05) | (1.55) | (0.40) | 1.47 | 5.67 |
Cash Flow/Sh
|
|||
| 0.00 | 0.00 | (0.31) | (0.01) | (0.02) | (0.13) | (0.40) | (5.51) | (3.90) | (1.74) |
Capex/Sh
|
|||
| (1.21) | (1.16) | (19.43) | (2.28) | (1.24) | (1.17) | (1.95) | (5.91) | (2.44) | 3.93 |
Free CF/Sh
|
|||
| 0.00 | 0.89 | (4.21) | 3.85 | 4.21 | 2.46 | 6.34 | 4.22 | 6.88 | 13.92 |
Book Value/Sh
|
|||
| 20 | 20 | 1 | 14 | 25 | 28 | 30 | 33 | 33 | 34 |
Shares
|
|||
| 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 58.27 | 21.80 |
PE Ratio
|
|||
| 2.09 | 2.09 | 2.09 | 11.44 | 19.17 | 17.49 | 18.06 | 10.34 | 4.69 | 6.83 |
PS Ratio
|
|||
| 0.00 | 0.00 | 0.00 | 4.94 | 4.73 | 7.80 | 9.01 | 18.20 | 9.06 | 8.74 |
PB Ratio
|
|||
| 3.51 | 3.51 | 3.51 | 9.47 | 15.62 | 15.59 | 16.55 | 10.80 | 5.09 | 6.87 |
EV/Sales
|
|||
| (1.95) | (1.95) | (1.95) | (6.89) | (13.04) | (14.57) | (26.80) | (13.59) | (27.76) | 31.14 |
EV/FCF
|
|||
| (24) | (23) | (26) | (32) | (30) | (29) | (46) | (13) | 49 | 193 |
Op' Cash Flow
|
|||
| (1) | 0 | 0 | 0 | 0 | (4) | (12) | (179) | (130) | (59) |
Capex
|
|||
| (24) | (23) | (26) | (32) | (31) | (32) | (58) | (192) | (81) | 134 |
FCF
|
|||
| — | 23 | 22 | 84 | 135 | 95 | 229 | 456 | 437 | 548 |
Working Cap'
|
|||
| — | 9 | 34 | 34 | 35 | 35 | 60 | 506 | 509 | 512 |
Total Debt
|
|||
| — | (16) | 13 | (47) | (91) | (57) | (141) | 111 | 173 | 24 |
Net Debt
|
|||
| — | 18 | (6) | 55 | 104 | 68 | 187 | 137 | 229 | 473 |
Sh' Equity
|
|||
| 0.00% | (52.61%) | (112.70%) | (45.50%) | (22.34%) | (30.82%) | (17.59%) | (5.09%) | 4.70% | 20.33% |
ROA
|
|||
| — | 0.00% | (164.13%) | (228.22%) | (127.77%) | (232.50%) | (42.41%) | (7.22%) | 5.84% | 13.65% |
ROIC
|
|||
| 0.00% | 11.54% | 13.16% | 48.76% | (36.27%) | (51.49%) | (28.39%) | (15.42%) | 19.39% | 54.24% |
ROE
|
|||
TransMedics Group, Inc. peers in Medical Devices
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| NEOG Neogen Corporation | $3.0B | 0.0× | Compare |
| BFLY Butterfly Network, Inc. | $2.6B | 0.0× | Compare |
| AXGN AxoGen, Inc. | $2.5B | 0.0× | Compare |
| IRTC iRhythm Holdings, Inc. | $3.7B | 0.0× | Compare |
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| UFPT UFP Technologies, Inc. | $2.3B | 31.6× | Compare |
| LIVN LivaNova PLC | $4.2B | 22.2× | Compare |
| ITGR Integer Holdings Corporation | $4.3B | 34.2× | Compare |
| INSP Inspire Medical Systems, Inc. | $2.0B | 15.1× | Compare |
TransMedics Group, Inc. (TMDX) key facts
- TransMedics Group, Inc. (TMDX) is a Medical Devices company in the Healthcare sector, listed on Nasdaq.
- TransMedics Group, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $605.5 million, up 37.1% from fiscal 2024.
- Net income was $190.3 million, or $5.60 per share (basic), a net margin of 31.4%.
- As of September 25, 2026, TMDX traded at $85.29, a market capitalization of $2.9 billion.
- At that price the stock trades at 19.3× trailing-twelve-month earnings and 4.4× sales.
- Return on equity was 54.2% and debt-to-equity 1.66.
TransMedics Group, Inc. (TMDX) Latest News
3 Sep
TMDX growth encounters rising margin pressure, prompting assessment of whether the stock remains worth buying amid these conflicting dynamics. Growth offset by margin pressure may moderately affect TMDX financial outlook and investor sentiment.
18 Aug
TransMedics targets a $2B market opportunity by expanding its organ preservation technology into kidney transplants and growing its presence in Europe. Kidney push into a $2B opportunity combined with European expansion represents major strategic moves that can significantly alter growth trajectory.
11 Aug
TransMedics Group, Inc. (TMDX) Q2 2026 earnings call transcript covers quarterly financial results, operational updates, and forward guidance. Q2 2026 earnings discussion and guidance directly shape investor views and TMDX valuation trajectory.
5 Aug
TransMedics Group Inc posted record revenue in Q2 2026 earnings call with emphasis on strategic initiatives driving growth. Record revenue and strategic moves signal major positive shift in financial trajectory and investor outlook.
TransMedics stock declined after missing Q2 earnings targets with contracting margins. Q2 earnings miss and margin contraction indicate financial pressures likely to affect near-term performance and sentiment.
TransMedics Group stock declines as market participants react to developments pressuring the company's near-term performance and sentiment. Stock price decline points to short-term pressure on valuation and sentiment without altering core long-term trajectory.
4 Aug
TransMedics Group Q2 earnings call highlighted revenue growth, operational updates on organ preservation systems, and forward guidance on market expansion and product adoption. Q2 earnings call delivers financial results and guidance that can shift near-term sentiment and valuation without altering long-term company trajectory.
TransMedics Group reported Q2 earnings along with analysis of key financial metrics. Q2 earnings release and key metrics can moderately influence stock valuation and near-term investor sentiment.
TransMedics Group reported Q2 earnings that missed analyst estimates. Q2 earnings shortfall signals weaker than expected financial results that can pressure near-term stock performance.
TransMedics Group reported financial results for the second quarter of 2026. Quarterly earnings releases disclose performance metrics that can shift near-term investor sentiment and valuation.
6 Jul
TransMedics Group completes strategic investment in PAD Aviation service GmbH. Aviation investment strengthens logistics supporting core organ transport operations.
1 Jul
TMDX stock rallies after an analyst issues a bullish note projecting 77% upside potential. Analyst price-target upgrade can lift near-term sentiment and trading volume without altering core fundamentals.
8 May
TransMedics Group Inc (TMDX) reported strong revenue growth in Q1 2026 earnings call highlights amid ongoing challenges. Strong revenue growth signals significant positive impact on TMDX's financial trajectory and investor sentiment.
6 May
TransMedics Group, Inc. (TMDX) released Q1 2026 earnings call transcript covering financial results, revenue growth, operational updates, and forward-looking guidance. Q1 2026 earnings transcript details quarterly financial performance, growth metrics, and strategic outlook, poised to significantly sway investor sentiment and stock trajectory.
TransMedics Group, Inc. (TMDX) released Q1 2026 earnings call summary detailing financial performance, operational updates, and future outlook. Q1 2026 earnings results and guidance represent major financial and strategic updates capable of significantly shifting investor sentiment and company trajectory.
TransMedics Group (TMDX) shares dipped after Q1 earnings and revenue missed expectations, with margins falling. Q1 earnings miss, revenue shortfall, and margin decline exert moderate pressure on TMDX's financial performance and market sentiment.
5 May
TransMedics Group released Q1 earnings call highlights, covering financial results, operational updates, and forward guidance for the organ transplant technology leader. Q1 earnings call highlights disclose revenue growth, margins, and guidance that significantly shape investor expectations and market performance.
TransMedics Group (TMDX) reported Q1 earnings, with key metrics highlighting revenue growth, profitability improvements, and operational performance amid organ transplant logistics expansion. Q1 earnings reports reveal financial health and guidance that significantly sway stock price and investor outlook.
TransMedics Group, Inc. (TMDX) reported first quarter 2026 financial results. Quarterly financial results disclosure significantly impacts stock performance and investor outlook.
TransMedics Group, Inc. (TMDX) Q1 earnings and revenues missed analyst estimates. Q1 earnings and revenue misses highlight weaker financial performance, likely causing moderate short-term pressure on stock price and investor sentiment.
29 Apr
TransMedics Group announces intent to create the first dedicated European transplant logistics network through strategic investment in PAD Aviation service GmbH. Strategic investment enables TransMedics to pioneer European transplant logistics, significantly expanding market reach and growth trajectory.
27 Apr
TransMedics Group, Inc. (TMDX) unveils CHOPS amid progressing clinical trials, with valuation screens indicating the stock is undervalued. Unveiling CHOPS and advancing trials mark major product developments poised to significantly elevate TMDX's competitive edge and investor sentiment.
14 Apr
TransMedics Group (TMDX) reports cash flow turnaround and ongoing fleet expansion, raising questions on whether these developments reshape its capital allocation strategy. Cash flow positivity and fleet expansion represent major strategic advancements poised to significantly influence TMDX's growth trajectory and market positioning.
26 Mar
TransMedics Group (TMDX) shares dropped 7.1% after the company announced expansion of its national Organ Care System (OCS) Transplant Platform ambitions. Expanding national OCS Transplant Platform ambitions constitutes a major strategic move that could significantly boost TMDX's growth and competitive positioning despite the immediate stock decline.
22 Mar
TransMedics CEO at conference outlined expansion of NOP program, plans for ENHANCE clinical trial, and strategic push into kidney transplantation market. CEO announcements detail major strategic expansions in NOP adoption, ENHANCE trial advancement, and entry into high-potential kidney transplant market.
11 Mar
Analysts raised price targets for TransMedics Group, Inc. (TMDX) following strong Q4 results. Analyst price target increases after Q4 results signal strong financial momentum likely to boost stock performance and investor sentiment.
5 Mar
TransMedics Group (TMDX) stock nears buy point as liver transplant demand surges. Surging liver transplant demand directly drives growth for TMDX's organ preservation systems, significantly impacting revenue and stock performance.
27 Feb
TransMedics discloses additional details on the impact of releasing the valuation allowance on deferred tax assets, which affects its previously reported fourth-quarter financial results. Releasing the valuation allowance recognizes deferred tax assets, improving reported financials and signaling future profitability but limited to accounting adjustments.
25 Feb
TransMedics Group, Inc. (TMDX) Q4 2025 earnings call summary details financial results, revenue growth, operational achievements, and future guidance. Q4 2025 earnings results and guidance represent major financial updates likely to shift investor sentiment and company trajectory.
TransMedics Group, Inc. (TMDX) stock rises as Q4 earnings and revenues beat estimates. Q4 earnings and revenue beats signal strong financial performance, boosting stock price and investor confidence.